Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib in Recurrent or Progressive Meningioma
NCT07428616Phase 2Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- May 2026
- Primary completion
- Feb 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib in meningioma, sponsored by Exelixis, Inc.. Started May 2026; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT07428616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428616.